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Abstract
Background: The Trifecta aortic bioprosthesis (St. Jude Medical, Inc., St. Paul, MN, USA) is a stented pericardial heart
valve with excellent preliminary results. Aim of the study was to evaluate its early clinical and hemodynamic
performances in a multicenter regional registry.
Methods: Between January 2011 and June 2012, 178 consecutive patients undergoing aortic valve replacement
with the Trifecta bioprosthesis were prospectively enrolled at 9 Italian centers. Clinical and echocardiographic
data were collectedat discharge, 6-months and at 1-year postoperatively.
Results: The average age was 75.4 ± 7.7 years,and 95 (53 %) were men. Indication for valve replacement included
stenosis in 123 patients (69 %), mixed lesions in 25 (14 %), and regurgitation in 30 (17 %). Ninety-three (52 %)
patients were in NYHA functional class III/ IV. Hospital mortality accounted for 5 (2.8 %) patients. No valve-related
perioperative complications were encountered. Median follow-up was 20.5 months (range: 1-34). Early (≤6 months)
complications included one thromboembolic event, one major bleeding, and 3 endocarditis (2 explants). Two late
(>6 months) thromboembolic events and two endocarditis (1 explant) were registered. No valve thrombosis or
structural deterioration were observed after discharge. At 30-months, freedom from all-cause mortality was 87 %,
freedom from valve-related mortality 99.4 %, freedom from endocarditis 97.5 %, and freedom from valve explants
98 %. At 1-year, mean gradients ranged from 8 to 16 mmHg, and effective orifice area indexes from 1.0 to
1.2 cm2/m2 for valve sizes from 19 to27 mm, respectively. No patients had severe prosthesis-patient mismatch.
Conclusions: Trifecta bioprosthesis provided favourable clinical and hemodynamic results over time.
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Background
The Trifecta aortic bioprosthesis (St. Jude Medical, Inc.,
St. Paul, MN, USA) is atri-leaflet stented pericardial
valve designed for the aortic supra-annular placement
[1]. Preliminary and early results about the performances
of the Trifecta valve are encouraging [1–5]. Outstanding
transvalvular gradients, excellent effective orifice area
(EOA) data, low incidence of prosthesis-patient mismatch
(PPM), also in patients with a small aortic annulus relative
to body size or during exercise and recovery, have been re-
ported [1–13]. On the other hand, given the fact that the
Trifecta valve has been introduced in the routine surgery
quite recently, large trials and long-term follow up data
are still lacking, especially concerning the structural de-
terioration and the hemodynamic performance of the
valve over time [14–16].
Therefore, the present study aims to evaluate early
clinical and hemodynamic performance of the Trifecta
bioprosthesis in a prospective regional Italian multicen-
ter registry.
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Methods
Patient selection
Between 1st January 2011 and 30th June 2012, all con-
secutive patients who received a St. Jude Trifecta valve
in aortic position were enrolled at nine Italian centres
located in the Lombardia region (Italy). Inclusion criteria
considered all the patients undergoing primary aortic
valve replacement (AVR) as isolated procedure or in
combination with other cardiac surgical procedures.
Ethic approval was granted by local Institutional Review
Boards, and the informed consent was collected from all
participants.
Surgical technique
Preoperative, anesthetic and postoperative management
followed each institutional policy and remained consistent
over the study period. Surgery was performed through a
median sternotomy or a mini-sternotomy approach with a
“J” incision. Cardiopulmonary bypass (CPB) and cannula-
tion techniques were defined according to the re-
quired surgical procedure. Mild-to-moderate systemic
hypothermia (32°–34 °C) or normothermia were ap-
plied. Myocardial protection was achieved according
to routine protocols of each institution. Right superior
pulmonary vein or main pulmonary artery venting
wereused. After the excision of the native aortic valve
or the previous aortic valve prosthesis and the decal-
cification of the aortic annulus, the commercial sizer
provided by the manufacturerwas used to choose for
correct valve size. Infra-annular or supra-annular im-
plantation techniques as well as interrupted or con-
tinuous sutures were performed following surgeon’s
preference. Generally, concomitant procedures accounted
for coronary artery bypass grafting, proximal aorta sur-
gery, mitral valve repair or replacement.
Data collection and follow-up
Clinical and echocardiographic data were recorded in a
prospective ad hoc database. All surviving patients were
postoperatively contacted and the follow-up was per-
formed at the local investigating sites by clinical evalu-
ation and echocardiograms at 6 months and 1 year
postoperatively. Where the follow-up was not possible
(deceased patients), medical data were collected by tele-
phone interviews of family members and/or confirmed
or clarified by general practitioners. Adverse events were
classified according to the standardized definitions from
the Society of Thoracic Surgeons/American Association
for Thoracic Surgery “Guidelines for reporting morbidity
and mortality and cardiac valve interventions” [17].
Events were classified as occurring early (≤6 months
after bioprosthetic implant) or late (>6 months). Follow-
up was closed on 30th June 2013.
Echocardiographic data
Transthoracic echocardiography data were recorded pre-
operatively, at discharge, as well as 6 months and 1-year
postoperatively. Standard prosthetic valve measurements
were obtained according to the criteria of the American
Society of Echocardiography [18]. Peak and mean trans-
valvular gradients, EOA, EOA index (EOAI), left ven-
tricular (LV) ejection fraction, end diastolic LV diameter,
LV mass, and LV mass index were all recorded. Aortic
valve regurgitation was classified as none (0/4), trivial
(1/4), moderate (2/4), moderate to severe (3/4) and se-
vere (4/4) according to the width of the regurgitation jet
compared to that of the outflow tract [19]. Finally, valve
PPM was defined as moderate (EOAI > 0.60 cm2/m2
and ≤ 0.85 cm2/m2) and severe (EOAI < 0.60 cm2/m2) as
previously reported [20].
Statistical analysis
Extracted database variables were tabulated using Micro-
soft Excel (Microsoft Corp). Statistical analysiswas com-
puted using SPSS, release 22.0 for Windows (IBM SPSS,
Inc., Chicago, IL, USA). Continuous datawere expressed
as mean ± SD, or median and interquartile range (IQR).
Percentages weredetermined for categorical variables. Dif-
ferences regarding repeated echocardiographic parameters
were evaluated with Kruskal-Wallis one-way analysis of
variance. Late adverse event rate were determined by
Kaplan-Meier method. A P value less than 0.05 was con-
sidered statistically significant.
Results
Population and operative data
The study population included 178 patients, with an
average age of age of 75.4 ± 7.7 years (range, 44 to
86 years) and included83 (46.6 %) women. Demographic
and preoperative data are listed in Table 1. New York
Heart Association (NYHA) class III was present in 78
(43.8 %) of the patients, whereas NYHA class IV in 15
(8.4 %). Mean logistic EuroSCORE was 7.7 ± 6.7 % (IQR,
3 to 11 %). Indications for AVR included stenosis in 123
patients (69.1 %), predominant regurgitation in 30 pa-
tients (16.9 %), and mixed disease in 25 patients (14 %).
Calcified or degenerative disease of the aortic valve
accounted for 155 (87.1 %) cases.
Concomitant procedures were performed in 97 (54.5 %)
patients, and included concomitant coronary artery bypass
graft (CABG) in 63 (35.4 %) cases (Table 2). A mini-
sternotomy approach was employed in 10 (5.6 %) patients.
The mean CPB and aortic cross clamp time (ACC) time
for isolated AVR were 79.9 ± 31.8 and 58.7 ± 25.8 min, re-
spectively. The prosthesis sizes were 19 mm in 31 patients
(17.4 %), 21 mm in 58 (32.6 %), 23 mm in 58 (32.6 %),
25 mm in 24 (13.5 %), and 27 mm in 7 (3.9 %).
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Early and medium-term clinical outcomes
Hospital mortality accounted for 5 (2.8 %) patients be-
cause of low cardiac output syndrome followed by multi-
organ failure (n = 1) or sepsis (n = 4). Re-exploration for
bleeding was required in 7 (3.9 %) cases, and 2 (1.1 %)
patients had stroke. Hospital stay was 11.1 ± 10.6 days
(IQR, 6 to 11 days). No valve-related perioperative com-
plications were recorded. Postoperative complications
are depicted in Table 2.
Median follow-up was 20.5 months (range: 1-30
months). During the follow-up, patients’ clinical status
significantly improved in all cases (P < 0.001), and
97.7 % of patients were in classes I or II at 1 year
follow-up (Fig. 1).
Early (≤6 months) and late (>6 months) adverse events
were all recorded (Table 3). There was only one early
thromboembolic event which caused a transient ische-
mic attack and two late thromboembolic events which
led to stroke. Three endocarditis occurred within six
months from the operation and two of them required
prosthesis explant. Two further endocarditis (1 explant)
were recorded during the late follow-up. None of the
registered endocarditis were primarily operated on for
native valve endocarditis. No valve thrombosis, hemolysis
and structural valve deterioration were registered after dis-
charge. Overall, freedom from all-cause mortality was
87.0 ± 2.5 % at 30 months, whereas freedom from valve re-
lated mortality was 99.4 ± 0.6 %, freedom from endocardi-
tis was 97.5 ± 1.2 %, and freedom from valve explants was
98.0 ± 1.1 % (Fig. 2).
Hemodynamic results
Hemodynamic results at discharge, 6 months and 1 year
are reported in Table 4 and Fig. 3. Mean and peak trans-
valvular gradients significantly decreased after AVR, with
Table 1 Preoperative patients details
Variablesa All implants (n = 178)
Demographics
Age, yrs 75.4 ± 7.7 (72-81)
Female, n (%) 83 (46.6)
BSA, m2 1.60 ± 0.33 (1.38-1.79)
Cardiac presentation
Previous AMI, n (%) 22 (12.4)
CAD, n (%) 68 (38.2)
History of AF, n (%) 25 (14.0)
Preoperative NYHA, n (%)
Class I 13 (7.3)
Class II 72 (40.4)
Class III 78 (43.8)
Class IV 15 (8.4)
Comorbidities
Hypertension, n (%) 136 (76.4)
Diabetes, n (%) 49 (27.5)
COPD, n (%) 24 (13.5)
PVD, n (%) 52 (29.2)
Dyslipidemia, n (%) 83 (46.6)
Renal dysfunction, n (%) 13 (7.3)
Renal failure-dialysis, n (%) 7 (3.9)
Logistic EuroSCORE, % 7.7 ± 6.7 (3.0-11.0)
Etiology
Calcified, n (%) 120 (67.4)
Rheumatic, n (%) 11 (6.2)
Degenerative, n (%) 35 (19.7)
Annular dilatation, n (%) 5 (2.8)
Endocarditis, n (%) 7 (3.9)
aFor continuous variables, mean ± SD (interquartile range); categorical data,
count (percentage)
AF atrial fibrillation, AMI acute myocardial infarction, BSA body surface area,
CAD coronary artery disease, COPD chronic obstructive pulmonary disease,
NYHA New York Heart Association, PVD peripheral vascular disease
Table 2 Perioperative patients details
Variablesa All implants (n = 178)
Valve size implanted, n (%)
19 mm 31 (17.4)
21 mm 58 (32.6)
23 mm 58 (32.6)
25 mm 24 (13.5)
27 mm 7 (3.9)
Operative data
Isolated AVR, n (%) 81 (45.5)
CABG, n (%) 63 (35.4)
ACC time, min 67.9 ± 41.4 (45-95)
CPB time, min 103.9 ± 45.7 (70-131)
Postoperative data
IABP, n (%) 6 (3.4)
Re-exploration for bleeding, n (%) 7 (3.9)
Stroke, n (%) 2 (1.1)
Respiratory failure, n (%) 14 (7.9)
Acute kidney injury, n (%) 24 (13.5)
Renal replacement therapy, n (%) 11 (6.2)
Atrial fibrillation, n (%) 79 (44.4)
Ventilation, hours 33.8 ± 98.8 (7-24)
ICU stay, hours 68.5 ± 119.2 (24-60)
Hospital mortality, n (%) 5 (2.8)
aFor continuous variables, mean ± SD (interquartile range); categorical data,
count (percentage)
ACC aortic cross clamp time, AVR aortic valve replacement, CABG coronary
artery bypass grafting, CPB cardiopulmonary bypass, IABP intra-aortic balloon
pump, ICU intensive care unit
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a significant reduction to approximately more than 50 %
of the preoperative values at six months. At discharge,
average mean gradients ranged from 7.4 to 13.5 mmHg
and average peak gradients ranged from 13.6 to
25.3 mmHg for valve sizes 19 to 25/27 mm, respectively.
At 1 year of follow-up, average mean gradients ranged
from 7.7 to 16.6 mmHg and average peak gradients
ranged from 14.1 to 29.5 mmHg for valve sizes 19 to 25/
27 mm, respectively. Significant increases in EOA and
EAOI were also observed. At discharge, EOAI ranged
from 1.6 to 2.2 cm2/m2 and from 1.4 to 2.5 cm2/m2at
1 year for valve sizes 19 to 25/27 mm, respectively. A
significant reduction of left ventricular mass index
(LVMI - g/m2) was documented at discharge (134.3 ±
42.2 g/m2), at 6 months (120.9 ± 40.9 g/m2), and 1-year
(123.2 ± 44.8 g/m2). At 6 months, valve prosthesis-patient
mismatch was mild-to-moderate in 19 (10.6 %) patients,
and severe PPM was not documented in any patient.
Finally, at discharge mild central aortic regurgitation
insufficiency was present in 31 (17.4 %) of the patients,
while moderate in 3 (1.7 %). No severe central regurgita-
tion was documented over-time. Paravalvular-leak detec-
tion is reported in Table 3.
Discussion
The present regional prospective multicenter registry
allowed the authors to record and analyze the early clin-
ical and echocardiographic resultsof the Trifecta bio-
prosthesisimplanted over a period of 24 months at nine
Italian hospital. The follow-up and the data showed a
good safety profile of the valve with no valve-related
perioperative complications, good perioperative mortal-
ity and overall survival, no valve thrombosis, no clinic-
ally significant hemolysis or structural deterioration. In
addition, the echocardiographic assessment of the hemo-
dynamicperformances of the Trifecta valve revealed nearly
physiological data and excellentperformances also when
compared with other pericardial prosthesis [6–13].
The increasing need for biological prosthesis related to
the rising age of the patients undergoing aortic valve re-
placement, is pushing biotechnologies toward the re-
search of the ideal prosthetic valve. Such a valve should
allow the surgeon to use an easy, quick and safe implant
technique with low risk for dehiscence or structural de-
generation in the long period [21]. The ideal bioprosth-
esis should also have a low intrinsic thrombogenicity
with no need for the anticoagulation therapy, and a
high-quality hemodynamic performance with low gradi-
ents, large EOA and good movement and coaptation of
the leaflet [1, 21, 22]. The Trifecta bioprosthesis is trying
to address those requests with its features, and it has
been designed with a concave, scalloped sewing ring for
a supra-annular implant with non-everting sutures [1].
Fig. 1 NYHA class. NYHA functional class over time (P < 0.001)
Table 3 Early and late adverse events
Variablesa Early (≤6 months) Late (>6 months)
Thromboembolism 1 (0.6) 2 (1.1)
Stroke 0 2 (1.1)
TIA 1 (0.6) 0
Valve thrombosis 0 0
Hemolysis 0 0
Major bleeding 1 (0.6) 0
Non-structural valve dysfunction 0 1 (0.6)
Paravalvular leak
Minor 6 (3.4) 6 (3.4)
Major 1 (0.6) 0
Structural valve deterioration 0 0
Endocarditis 3 (1.7) 2 (1.1)
Prosthesis explant 2 (1.1) 1 (0.6)
Mortality Valve-related 1 (0.6) 0
aCount (Percentage)
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Ugur et al. [21] demonstrated that AVR with Trifecta
bioprosthesis can be safely performed with non everting
pledget-reinforced sutures, everting mattress sutures with
or without pledgets, simple sutures or continuous suture
techniques giving the surgeon a wide range of choice in
terms of implant technique. In our experience, infra-
annular or supra-annular implantation techniques as well
as interrupted or continuous sutures were performed fol-
lowing surgeon’s preference and the low rate of paravalvu-
lar leak confirmed the ease of implantability of the valve.
However, an appropriate sizing and annular decalcification
are mandatory to avoid paravalvular leaks, as far as the
prevention of stent distortion which can abolish the bene-
fits of a cuff designed to conform to the native annulus
after implantation [2].
In addition, the nearly physiological hemodynamic
performances of Trifecta bioprosthesis could decrease
the need of stentless valves which, on the contrary, re-
quire a substantial learning curve, technically demanding
implantation and an aortic root replacement in case of
failure of the prosthesis [23]. Its excellent hemodynamic
performances could also simplify the implant process
avoiding additional root and annular enlargement
[1–5, 24]. As a matter of fact, the external mounting
of leaflets allows for a wider opening, and the expan-
sible stentcould limit impedance to flow during high
flow conditions as during exercise [12]. The nearly cylin-
drical opening of the Trifecta bioprosthesis during systole
provides gradients and EOAs that result superior to any
other available stented aortic prosthesis and approach
those of stentless valves [1]. Bavaria et al. [1] provided ex-
cellent hemodynamic performances of the Trifecta bio-
prosthesis in more than 1000 patients enrolled at 31
centers, documenting at the time of discharge an average
mean gradients ranging from 9.3 to 4.1 mmHg and an
EOA ranging from 1.58 to 2.50 cm2 for valve sizes 19 to
29 mm, respectively. Clinically, they also demonstrated a
freedom from NYHA class III or IV symptoms of 96.1 %
[1]. The present multicenter regional registry confirmed
these excellent clinical and hemodynamic performances.
In consonance with Bavaria’s study [1], the present one re-
ports data after more than 1-year of follow-up, whereas
Fig. 2 Follow-up data. Freedom from all-cause mortality (a), freedom form valve-related mortality (b), freedom from endocarditis (c), and freedom
from valve explant (d)
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the majority of the published papers documented the per-
formances of the Trifecta bioprosthesis at discharge or at
a maximum follow-up of 6 months [12, 24].
In our multicenter registry, the favorable hemodynamic
led to a low incidence of PPM which was mild-to moder-
ate in 19 (11 %) patients only, while severe mismatch was
never detected. Literature suggests thatPPM is related to a
significant increase in all-cause andcardiac-related mor-
tality over long-term follow-up after AVR,since the per-
sistent LV afterload imposedby PPM may impair the
postoperative recovery of the coronaryflow reserve and
hinder the regression of LV hypertrophy anddysfunc-
tion [25]. In our experience, LVMI significantly de-
crease from preoperative values up to 1 year after
surgery, suggesting a positive effect of the bioprosthetic
valve on the myocardial hypertrophy.
Finally, we were able also to confirm the postoperative
satisfactory results in terms of valve thrombosis, struc-
tural deterioration freedom from all-cause mortality,
valve-related mortality, endocarditis and valve explants.
Therefore, the present data are comparable to those pre-
viously described for the Trifecta bioprosthesis and other
bioprosthetic aortic valves [1–13, 26–28]. During the
follow-up, we observed five endocarditis with three ex-
plant, but no signs of structural valve deterioration were
detected. Bavaria et al. [1] reported one explant for early
deteriorationover 1014 enrolled patientsandthe explanted
valve did not demonstrate thickeningor calcification of the
cusps. However, despite the use of anticalcification agents
and the elimination of a tacking suture at the top of
the commissures so to decrease the risk of tearing,
early degeneration is still possible from an accelerated
Table 4 Echocardiographic data over time
Variablesa Preoperative Discharge 6 months 1 year
Size 19 mm (n) 31 29 29 25
Peak gr, (mmHg)b 76.1 ± 28.7 25.3 ± 9.5 24.1 ± 8.2 29.5 ± 11.0
Mean gr (mmHg)b 45.7 ± 18.3 13.5 ± 5.7 13.2 ± 4.4 16.6 ± 5.8
EOA (cm2)b 1.0 ± 0.5 1.6 ± 0.4 1.4 ± 0.4 1.4 ± 0.1
EOAI (cm2/m2)b 0.2 ± 0.4 1.1 ± 0.7 1.0 ± 0.1 1.0 ± 0.1
LVMI (g/m2)b 136.2 ± 8.2 124.2 ± 23.3 118.1 ± 44.6 123.4 ± 40.4
EF (%) 58.7 ± 9.4 55.5 ± 8.2 57.3 ± 5.9 58.4 ± 6.1
Size 21 mm (n) 58 57 56 51
Peak gr (mmHg)b 87.7 ± 25.6 18.2 ± 5.2 17.9 ± 5.2 18.3 ± 5.2
Mean gr (mmHg)b 54.7 ± 17.3 9.8 ± 2.9 9.4 ± 2.7 9.9 ± 3.0
EOA (cm2)b 0.7 ± 0.2 1.9 ± 0.9 2.0 ± 0.3 2.1 ± 0.5
EOAI (cm2/m2)b 0.5 ± 0.1 1.1 ± 0.3 1.2 ± 0.3 1.4 ± 0.4
LVMI (g/m2)b 146.1 ± 22.8 142.2 ± 52.3 120.5 ± 48.7 127.7 ± 57.1
EF (%) 58.4 ± 7.9 56.4 ± 8.4 56.8 ± 8.2 55.9 ± 8.4
Size 23 mm (n) 58 56 56 53
Peak gr (mmHg)b 77.6 ± 29.9 14.4 ± 5.0 15.1 ± 4.8 16.6 ± 5.4
Mean gr (mmHg)b 47.8 ± 20.3 7.6 ± 2.3 8.2 ± 3.1 9.1 ± 3.2
EOA (cm2)b 1.1 ± 0.6 2.1 ± 0.3 1.9 ± 0.3 1.8 ± 0.2
EOAI (cm2/m2)b 0.6 ± 0.8 1.1 ± 0.3 1.0 ± 0.1 1.2 ± 0.1
LVMI (g/m2)b 140.8 ± 25.8 135.2 ± 37.3 123.4 ± 33.2 125.9 ± 30.8
EF (%) 55.7 ± 8.9 52.4 ± 8.9 54.5 ± 9.5 53.4 ± 8.6
Size 25/27 mm (n) 31 31 31 27
Peak gr (mmHg)b 62.7 ± 28.9 13.6 ± 5.2 14.4 ± 4.6 14.1 ± 4.7
Mean gr (mmHg)b 36.7 ± 18.0 7.4 ± 2.8 8.2 ± 2.5 7.7 ± 2.4
EOA (cm2)b 1.2 ± 0.5 2.2 ± 0.8 2.0 ± 0.8 2.5 ± 1.3
EOAI (cm2/m2)b 0.9 ± 0.4 1.2 ± 0.4 1.2 ± 0.5 1.5 ± 0.5
LVMI (g/m2)b 157.0 ± 53.1 126.2 ± 42.9 118.4 ± 24.3 100.9 ± 41.0
EF (%) 54.5 ± 11.1 50.8 ± 9.7 55.5 ± 8.9 56.2 ± 9.5
aData are expressed as mean ± SD
bp < 0.001 between discharge or 6-month or 1-year values versus preoperative values
EF ejection fraction, EOA effective orifice area, EOAI effective orifice are index, LVMI left ventricular mass index
Mariscalco et al. Journal of Cardiothoracic Surgery  (2015) 10:169 Page 6 of 8
immunologicreaction to the pericardial tissueor because
of a reaction to the suture material [14–16].
The present study has limitations. First, it enrolled a
relatively small sample size, although it represents one
of the largest patient group treated with the Trifecta bio-
prosthesis to date [1–3]. Second, there is the lack of a
control group for comparison with other bioprosthetic
and stentless valves, a limitation shared with other stud-
ies [1–5]. Third, our patient population is heterogeneous
with reference to the surgical access (full-sternotomy vs
mini-sternotomy) and implant techniques (infra-annular
vs supra-annular or interrupted vs continuous sutures),
which constituted a minor possible confounder in clin-
ical and performance assessment of the present bioprosth-
esis. Finally, the follow-up time is another limitation of the
present study since the Trifecta bioprosthesis has been
commercialized few years ago, and long-term follow-up
data are certainly mandatory to confirm its promising
clinical and hemodynamic results.
Conclusion
In conclusion, the present prospective multicenter regional
study provided favourable clinical and hemodynamic re-
sults for the Trifecta bioprosthesis, showing ease of im-
plantation, low incidence of early valve degeneration and
valve-related morbidity. The Trifecta aortic valve should be
considered as a good option and alternative to other
biologicalstented aortic valves. However, further studies
are mandatory to assess the long-term results, confirm-
ing the early documented favorable data.
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